Three Targets Beyond PSMA in Prostate Cancer Radioligand Therapy

Radioligand therapy transformed advanced prostate cancer care with PSMA targeting. Now experts eye options for PSMA-resistant or low-expression cases. At APCCC 2026, Dr. Ken Herrmann named ACP3, B7-H3, and STEAP1/STEAP2 as top priorities. These could reach patients (outside clinical trials) in four to five years. ACP3, or prostatic acid phosphatase, binds tighter than PSMA in […]

Christopher Sweeney at ASCO GU 2026: Managing mHSPC and How Treatment Now Extends Overall Survival

Christopher Sweeney is a leading medical oncologist specializing in prostate cancer and a key figure in shaping modern treatment standards for advanced disease. In his ASCO GU 2026 talk he translates decades of clinical‑trial data into a practical, numbers‑driven framework for mHSPC therapy. His talk on metastatic hormone‑sensitive prostate cancer (mHSPC) is built around a […]